WO2021054912A1 - Effervescent tablet formulations comprising dapagliflozin and metformin - Google Patents
Effervescent tablet formulations comprising dapagliflozin and metformin Download PDFInfo
- Publication number
- WO2021054912A1 WO2021054912A1 PCT/TR2020/050687 TR2020050687W WO2021054912A1 WO 2021054912 A1 WO2021054912 A1 WO 2021054912A1 TR 2020050687 W TR2020050687 W TR 2020050687W WO 2021054912 A1 WO2021054912 A1 WO 2021054912A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- effervescent tablet
- composition according
- sodium
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 238000009472 formulation Methods 0.000 title claims abstract description 50
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 37
- 229960003105 metformin Drugs 0.000 title claims abstract description 35
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title claims abstract description 34
- 229960003834 dapagliflozin Drugs 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 239000003826 tablet Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 13
- 229960001031 glucose Drugs 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 11
- 229960000913 crospovidone Drugs 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 11
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 235000015165 citric acid Nutrition 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 9
- 239000007884 disintegrant Substances 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000004376 Sucralose Substances 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 8
- 229960001855 mannitol Drugs 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000008240 homogeneous mixture Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical group 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical group 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001099 ammonium carbonate Substances 0.000 claims description 2
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 229910021538 borax Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229940096516 dextrates Drugs 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 2
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 claims description 2
- 229940043276 diisopropanolamine Drugs 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004418 trolamine Drugs 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 14
- 239000008103 glucose Substances 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008118 PEG 6000 Substances 0.000 description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 5
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 229940036941 metformin and dapagliflozin Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000007021 Prunus avium Species 0.000 description 1
- 235000010401 Prunus avium Nutrition 0.000 description 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 1
- 235000013992 Prunus padus Nutrition 0.000 description 1
- 235000013647 Prunus pensylvanica Nutrition 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Definitions
- the invention relates to formulations comprising dapagliflozin or a pharmaceutically acceptable salt thereof combined with metformin or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to the effervescent formulation of dapagliflozin and metformin with the desired properties.
- Diabetes mellitus is a lifelong chronic disease resulting from the pancreas's inability to produce enough insulin or the body's ability to use insulin effectively and it continues with the reduction of insulin-producing cells. Blood glucose rises with absent or non-functioning insulin hormone. The resulting high blood sugar causes classical symptoms such as polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger).
- type 1 diabetes type 1
- type 2 diabetes type 2 diabetes
- gestational diabetes is seen in pregnant women who develop high blood sugar levels.
- Type 1 diabetes is caused by the body's inability to produce insulin, requiring insulin injection.
- type 2 diabetes the body either resists the effects of insulin or does not produce enough insulin to maintain a normal glucose level.
- type 2 diabetes is the most common type, affecting more than 171 million people worldwide.
- Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2).
- SGLT2 is a carrier responsible for the reabsorption of most of the glucose from the lumen of the renal tubule.
- SGLT2 is expressed in proximal renal tubules.
- dapagliflozin reduces the reabsorption of the filtered glucose and lowers the renal threshold for glucose. This improves urinary glucose excretion and blood glucose control.
- Dapagliflozin also known as (1S)-1 ,5-Anhydro-1-C-[4-chloro-3-[(4- ethoxyphenyl)methyl]phenyl]-D-glucitol or (2S,3R,4R,5S,6R)-2-(3-(4-etoxybenzyl)-4- chlorophenyl)-6-hydroxymethyltetrahydro-2FI-pyran-3,4,5-triol is represented by the structure of Formula I.
- Dapagliflozin was first disclosed in patent US 6515117 (2003, Bristol-Myers Squibb).
- Metformin is an antihyperglycemic agent that improves glucose tolerance and lowers both basal and postprandial plasma glucose levels by different mechanisms than other oral antidiabetic agents. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.
- Metformin also known as N, N- dimethylimidodicarbonimidic diamide or 1 ,1 -Dimethylbiguanide or N, N- dimethyldiguanide or N, N-Dimethylguanylguanidine, is represented by the chemical structure in Formula II.
- EP2498758B1 discloses bilayer tablets comprising metformin and dapagliflozin.
- EP2498759B1 discloses a process for the preparation of an immediate release formulation comprising a combination of dapagliflozin and metformin.
- WO 2017/098481 discloses an effervescent combination comprising metformin with retained carbon dioxide content of at least 90% of the input blend and a different antidiabetic agent.
- Unexamined patent TR2012/02948 discloses a tablet form comprising a combination of metformin hydrochloride and dapagliflozin and a core tablet coated with a coating solution containing extended release metformin and dapagliflozin.
- the main object of effervescent tablet formulations comprising dapagliflozin or a pharmaceutically acceptable salt thereof with metformin or a pharmaceutically acceptable salt thereof is to obtain a stable formulation with good flowability and that does not adhere to the manufacturing apparatus. Another object is to obtain an effervescent formulation that is well dispersed and dissolved in water, thereby having high bioavailability. Effervescent tablet formulations with good solubility provide a homogeneous mixture, which increases patient compliance.
- effervescent tablet formulations are becoming an increasingly important issue in patient compliance, compared to traditional solid dosage forms such as capsules and tablets for oral administration. Compliance is even more important, especially in patients having difficulty in swallowing.
- effervescent tablet formulations are one of the advantageous ways of delivering drugs comprising dapagliflozin and metformin, providing better patient compliance along with the recommended pharmaceutical treatments. It is known that it is difficult to develop effervescent tablet formulations for several different reasons. First, it can cause non-compliance problems if it leaves an unpleasant and bitter taste when dispersed in water. Moreover, these tablets should be very porous and not too hard.
- Effervescent tablets should ensure rapid dissolution of the drug to provide a neutral, clear solution with a pleasant taste, without leaving any residues or precipitates behind. Therefore, there is a need for the development of an effervescent formulation that has a desired dissolution time and a desired solubility without leaving any residues and precipitates after dissolution and has an acceptable taste for patients. Dissolution problems of the drug and formulation, unpleasant and bitter taste arising from water dissolution are problems that need to be overcome. Finally, any effervescent tablet with appropriate organoleptic and pharmacokinetic properties should also be produced in commercially appropriate quantities and yields and simpler methods. When evaluated within the framework of the mentioned problem, it is clear that an innovation in the art is needed for effervescent formulations comprising dapagliflozin and metformin.
- the object of the present invention is to provide an improved effervescent tablet formulation comprising dapagliflozin or a pharmaceutically acceptable salt thereof combined with metformin or a pharmaceutically acceptable salt thereof that overcomes the above mentioned problems and beneficial in the treatment of type 2 diabetes using suitable excipients.
- the object of the present invention is to overcome the above-mentioned problems related to effervescent formulations such as obtaining the desired solubility of the drug or formulation without leaving any residues or precipitates after dissolution and providing a better flavor for patients, by using suitable excipients together and in specific proportions.
- Another aim of the present invention is to increase flowability during manufacture and to eliminate the problem of adhesion to the manufacturing apparatus thanks to the formulation obtained.
- another object is to provide effervescent tablet formulations that is water-soluble and remain stable throughout their shelf life.
- Main difficulties when two or more molecules are combined in the same pharmaceutical dosage form are a) ensuring compatibility between different active substances and / or excipients used with active substances, (b) ensuring therapeutic compatibility between the active ingredients, taking into account the pharmacokinetic and / or biopharmaceutical properties, such as the posology of the combination, to obtain effective and safe plasma levels of both active ingredients. Therefore, the selection of the active ingredients and suitable excipients to be used together and the amounts at which they are used are very important.
- a pharmaceutical formulation comprising a combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.
- the effervescent tablet formulation comprising dapagliflozin and metformin that is stable and has very good dissolution and solubility rate, thereby high bioavailability is obtained by the present invention.
- the present invention is an effervescent tablet formulation comprising dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.
- dapagliflozin or a pharmaceutically acceptable salt thereof being present in the ratio of 0,001 to 5%, preferably 0,01 to 1%, and more preferably 0,05 to 0,2% by weight of the total formulation and metformin or a pharmaceutically acceptable salt thereof being present in the ratio of 1 to 50%, preferably 5 to 30%, and more preferably 10 to 20% by weight of the total formulation has enabled both active substances to reach an effective and safe plasma level, ensured therapeutic compatibility between the active ingredients and compatibility between active ingredients and excipients.
- Pharmaceutical formulations of the present invention may also comprise one or more pharmaceutically acceptable excipients.
- Pharmaceutically acceptable excipients include, but are not limited to fillers, alkali agents, acidic agents, sweeteners, aromatic agents, disintegrants, lubricants, or mixtures thereof.
- the amount of filler in the formulation according to the invention is 1 to 80%, preferably 3 to 70%, more preferably 5 to 60% by weight in the total composition.
- the filler is sugars, mannitol, sorbitol, sucrose, inorganic salts, calcium salts, polysaccharides, dextrose, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixtures, xylitol, trehalose or mixtures thereof.
- mannitol is used in the invention.
- the use of the total active ingredient to the filler at the ratio of 0,01 to 30, preferably 0,015 to 20, more preferably 0,05 to 10, and most preferably 0,1 to 5 allowed a more stable effervescent tablet formulation of dapagliflozin and metformin.
- metformin active ingredient with low compressibility rate to the filler in the ratio of 0,01 - 30, preferably 0,05 - 20, more preferably 0,07 - 10 and most preferably 0,16 - 4 allowed a more stable effervescent tablet formulation of dapagliflozin and metformin.
- effervescent formulations comprise acidic agents and alkali agents that react quickly in the presence of water by releasing carbon dioxide such as carbonates or bicarbonates.
- the choice of acidic-alkali agent and their ratio to each other is important in terms of stability, disintegration time and water solubility.
- the ratio of the acidic agent to the alkaline agent should be carefully determined to obtain a neutral solution that doesn’t leave any residues or precipitates after dissolution.
- the high amount of acidic agent can adversely affect the gastrointestinal tract.
- high amounts of alkaline agents (especially hydrophobic agents) lead to blurry and precipitated solution and damage the gastrointestinal tract.
- the amount of alkali agent in the formulation of the invention is 0,5 to 60%, preferably 1 to 50%, more preferably 2 to 40% by weight in the total composition.
- alkali agent is selected from sodium bicarbonate, sodium glycine carbonate, ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, trolamine or mixtures thereof.
- sodium bicarbonate is used in the invention.
- the amount of acidic agent in the formulation of the invention is between 0,5 and 60% by weight, preferably between 1 and 50%, more preferably between 2 and 40% by weight in the total composition
- the acidic agent is selected from the group comprising malic acid, fumaric acid, citric acid, adipic acid, acetic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, tartaric acid or mixtures thereof.
- citric acid is used in the invention.
- the amount of sweetener in the formulation of the invention is in the ratio of 0,01 to 30%, preferably 0,05 to 20%, more preferably 0,1 to 10% by weight of the total composition.
- sweeteners comprise, but are not limited to, saccharin sodium, aspartame, sucralose, glucose, lactose, fructose and other sugars, or taumatin, mogroside, inulin, mannitol, sorbitol, xylitol, erythritol and other sugar alcohols or mixtures thereof.
- sucralose is used in the invention.
- the amount of the aroma in the formulation of the invention is in the ratio of 0,01 to 30%, preferably 0,05 to 20%, more preferably 0,1 to 10% by weight of the total composition.
- aromatic agents of the invention comprise, but are not limited to, fruit flavors such as orange, banana, strawberry, cherry, bird cherry, lemon, and other flavors such as cardamom, anise, peppermint, menthol, vanillin and ethyl vanillin, and mixtures thereof.
- disintegrant is selected from alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulfate, sodium carboxymethyl cellulose, croscarmellose sodium, crospovidone, carboxymethyl cellulose calcium, doucat sodium, guar gum, low substitute hydroxypropyl cellulose, polyacrylene potassium, poloxamer, povidone, sodium alginate, sodium glycine carbonate, sodium lauryl sulfate or mixtures thereof.
- crospovidone is used in the invention.
- crospovidone as a disintegrant in the ratio of 0,1% to 15%, preferably 1% to 8%, more preferably 2% to 4% by weight in the total composition allowed for a formulation with the desired water solubility time and improved patient compliance.
- the ratio of the active ingredient dapagliflozin with low solubility to the disintegrant in the range of 0,001 - 5, preferably 0,00125 - 1 , more preferably 0,01 - 0,5, more preferably 0,0125 - 0,1 by weight in the formulation allowed for an effervescent tablet formulation of dapagliflozin and metformin with very good dissolution and solubility ratio, thereby high bioavailability, forming a neutral and clear solution that doesn’t leave any residues or precipitates after dissolution.
- Polyethylene glycol is a water-soluble lubricant and is stable. Polyethylene glycol also does not cause over-mixing problems and is not hygroscopic. Since it is not hygroscopic, it does not harm the manufacture apparatus. Furthermore, polyethylene glycol can perform more than one function in the formulation of the present invention. For example, it can function both as a lubricant and as a stabilizer. This helps the formulation to remain stable throughout its shelf life.
- PEG 6000 is used in the invention.
- the amount of lubricant is 0,1 to 30%, preferably 0,5 to 15%, more preferably 1 to 5% by weight in the total composition.
- Another embodiment of the present invention is a method for the preparation of effervescent tablet formulation, comprising the following steps; a. Granulating, drying and sieving dapagliflozin, metformin and mannitol using alcohol b. Mixing the granules with sodium bicarbonate, citric acid, sucralose, aroma and crospovidone to obtain homogeneity c. Adding PEG 6000 and mixing further for a short period of time to obtain a homogeneous mixture. d. Finalising the mixture and pressing into the tablets under low humidity conditions adimlarini igermektedir.
- the above-mentioned pharmaceutical formulation is prepared as follows:
- the above-mentioned pharmaceutical formulation is prepared as follows:
- the above-mentioned pharmaceutical formulation is prepared as follows:
- this invention provides an effervescent tablet formulation of dapagliflozin and metformin that is stable and has very good dissolution and solubility ratio, thereby high bioavailability, that does not stick to the manufacture apparatus during production, creates a stable, neutral and clear solution against moisture, does not leave any residues or precipitates after dissolution and provides a delicious taste, does not leave an unpleasant and bitter taste.
Abstract
The invention relates to effervescent tablet formulations comprising dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.
Description
EFFERVESCENT TABLET FORMULATIONS COMPRISING DAPAGLIFLOZIN
AND METFORMIN
Field of the Invention
The invention relates to formulations comprising dapagliflozin or a pharmaceutically acceptable salt thereof combined with metformin or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to the effervescent formulation of dapagliflozin and metformin with the desired properties.
Background of the Invention
Diabetes mellitus, known as diabetes, is a lifelong chronic disease resulting from the pancreas's inability to produce enough insulin or the body's ability to use insulin effectively and it continues with the reduction of insulin-producing cells. Blood glucose rises with absent or non-functioning insulin hormone. The resulting high blood sugar causes classical symptoms such as polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger). Currently, there are three types of diabetes: type 1 diabetes (type 1), type 2 diabetes (type 2) and gestational diabetes. Gestational diabetes is seen in pregnant women who develop high blood sugar levels. Type 1 diabetes is caused by the body's inability to produce insulin, requiring insulin injection. Finally, with type 2 diabetes, the body either resists the effects of insulin or does not produce enough insulin to maintain a normal glucose level. Of these three types of diabetes, type 2 diabetes is the most common type, affecting more than 171 million people worldwide.
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2). SGLT2 is a carrier responsible for the reabsorption of most of the glucose from the lumen of the renal tubule. SGLT2 is expressed in proximal renal tubules. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of the filtered glucose and lowers the renal threshold for glucose. This improves urinary glucose excretion and blood glucose control. Dapagliflozin, also known as (1S)-1 ,5-Anhydro-1-C-[4-chloro-3-[(4-
ethoxyphenyl)methyl]phenyl]-D-glucitol or (2S,3R,4R,5S,6R)-2-(3-(4-etoxybenzyl)-4- chlorophenyl)-6-hydroxymethyltetrahydro-2FI-pyran-3,4,5-triol is represented by the structure of Formula I.
Formula I
Dapagliflozin was first disclosed in patent US 6515117 (2003, Bristol-Myers Squibb). Metformin is an antihyperglycemic agent that improves glucose tolerance and lowers both basal and postprandial plasma glucose levels by different mechanisms than other oral antidiabetic agents. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease. Metformin, also known as N, N- dimethylimidodicarbonimidic diamide or 1 ,1 -Dimethylbiguanide or N, N- dimethyldiguanide or N, N-Dimethylguanylguanidine, is represented by the chemical structure in Formula II.
Formula II
Metformin was first disclosed in patent US 3174901 (1965, Jan Marcel Didier Aron- Samuel).
EP2498758B1 discloses bilayer tablets comprising metformin and dapagliflozin.
EP2498759B1 discloses a process for the preparation of an immediate release formulation comprising a combination of dapagliflozin and metformin.
WO 2017/098481 discloses an effervescent combination comprising metformin with retained carbon dioxide content of at least 90% of the input blend and a different antidiabetic agent.
Unexamined patent TR2012/02948 discloses a tablet form comprising a combination of metformin hydrochloride and dapagliflozin and a core tablet coated with a coating solution containing extended release metformin and dapagliflozin.
The main object of effervescent tablet formulations comprising dapagliflozin or a pharmaceutically acceptable salt thereof with metformin or a pharmaceutically acceptable salt thereof is to obtain a stable formulation with good flowability and that does not adhere to the manufacturing apparatus. Another object is to obtain an effervescent formulation that is well dispersed and dissolved in water, thereby having high bioavailability. Effervescent tablet formulations with good solubility provide a homogeneous mixture, which increases patient compliance.
Various formulations and methods are known in the art for the preparation of effervescent tablet formulations. However, effervescent tablet formulations are becoming an increasingly important issue in patient compliance, compared to traditional solid dosage forms such as capsules and tablets for oral administration. Compliance is even more important, especially in patients having difficulty in swallowing. For these reasons, effervescent tablet formulations are one of the advantageous ways of delivering drugs comprising dapagliflozin and metformin, providing better patient compliance along with the recommended pharmaceutical treatments.
It is known that it is difficult to develop effervescent tablet formulations for several different reasons. First, it can cause non-compliance problems if it leaves an unpleasant and bitter taste when dispersed in water. Moreover, these tablets should be very porous and not too hard. These porous tablets tend to be quite sensitive to moisture. As a result, they may carry some stability issues. Effervescent tablets should ensure rapid dissolution of the drug to provide a neutral, clear solution with a pleasant taste, without leaving any residues or precipitates behind. Therefore, there is a need for the development of an effervescent formulation that has a desired dissolution time and a desired solubility without leaving any residues and precipitates after dissolution and has an acceptable taste for patients. Dissolution problems of the drug and formulation, unpleasant and bitter taste arising from water dissolution are problems that need to be overcome. Finally, any effervescent tablet with appropriate organoleptic and pharmacokinetic properties should also be produced in commercially appropriate quantities and yields and simpler methods. When evaluated within the framework of the mentioned problem, it is clear that an innovation in the art is needed for effervescent formulations comprising dapagliflozin and metformin.
Background and Description of the Invention
The object of the present invention is to provide an improved effervescent tablet formulation comprising dapagliflozin or a pharmaceutically acceptable salt thereof combined with metformin or a pharmaceutically acceptable salt thereof that overcomes the above mentioned problems and beneficial in the treatment of type 2 diabetes using suitable excipients.
The object of the present invention is to overcome the above-mentioned problems related to effervescent formulations such as obtaining the desired solubility of the drug or formulation without leaving any residues or precipitates after dissolution and providing a better flavor for patients, by using suitable excipients together and in specific proportions.
Another aim of the present invention is to increase flowability during manufacture and to eliminate the problem of adhesion to the manufacturing apparatus thanks to the
formulation obtained. In addition, another object is to provide effervescent tablet formulations that is water-soluble and remain stable throughout their shelf life.
Main difficulties when two or more molecules are combined in the same pharmaceutical dosage form are a) ensuring compatibility between different active substances and / or excipients used with active substances, (b) ensuring therapeutic compatibility between the active ingredients, taking into account the pharmacokinetic and / or biopharmaceutical properties, such as the posology of the combination, to obtain effective and safe plasma levels of both active ingredients. Therefore, the selection of the active ingredients and suitable excipients to be used together and the amounts at which they are used are very important.
In order to achieve all the objectives mentioned above and those that may emerge from the detailed description below, a pharmaceutical formulation has been developed comprising a combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.
The effervescent tablet formulation comprising dapagliflozin and metformin that is stable and has very good dissolution and solubility rate, thereby high bioavailability is obtained by the present invention. The present invention is an effervescent tablet formulation comprising dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.
Surprisingly, it has been found that, according to this embodiment of the present invention, dapagliflozin or a pharmaceutically acceptable salt thereof being present in the ratio of 0,001 to 5%, preferably 0,01 to 1%, and more preferably 0,05 to 0,2% by weight of the total formulation and metformin or a pharmaceutically acceptable salt thereof being present in the ratio of 1 to 50%, preferably 5 to 30%, and more preferably 10 to 20% by weight of the total formulation has enabled both active substances to reach an effective and safe plasma level, ensured therapeutic compatibility between the active ingredients and compatibility between active ingredients and excipients.
Pharmaceutical formulations of the present invention may also comprise one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients include, but are not limited to fillers, alkali agents, acidic agents, sweeteners, aromatic agents, disintegrants, lubricants, or mixtures thereof.
The amount of filler in the formulation according to the invention is 1 to 80%, preferably 3 to 70%, more preferably 5 to 60% by weight in the total composition.
In the formulation of the invention, the filler is sugars, mannitol, sorbitol, sucrose, inorganic salts, calcium salts, polysaccharides, dextrose, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixtures, xylitol, trehalose or mixtures thereof. Preferably mannitol is used in the invention.
Surprisingly, according to this embodiment of the present invention, the use of the total active ingredient to the filler at the ratio of 0,01 to 30, preferably 0,015 to 20, more preferably 0,05 to 10, and most preferably 0,1 to 5 allowed a more stable effervescent tablet formulation of dapagliflozin and metformin.
Surprisingly, according to this embodiment of the present invention, the use of metformin active ingredient with low compressibility rate to the filler in the ratio of 0,01 - 30, preferably 0,05 - 20, more preferably 0,07 - 10 and most preferably 0,16 - 4 allowed a more stable effervescent tablet formulation of dapagliflozin and metformin.
In general, effervescent formulations comprise acidic agents and alkali agents that react quickly in the presence of water by releasing carbon dioxide such as carbonates or bicarbonates. The choice of acidic-alkali agent and their ratio to each other is important in terms of stability, disintegration time and water solubility. The ratio of the acidic agent to the alkaline agent should be carefully determined to obtain a neutral solution that doesn’t leave any residues or precipitates after dissolution. The high amount of acidic agent can adversely affect the gastrointestinal tract. In addition, high amounts of alkaline agents (especially hydrophobic agents) lead to blurry and precipitated solution and damage the gastrointestinal tract.
The amount of alkali agent in the formulation of the invention is 0,5 to 60%, preferably 1 to 50%, more preferably 2 to 40% by weight in the total composition.
In the formulation of the invention, alkali agent is selected from sodium bicarbonate, sodium glycine carbonate, ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, trolamine or mixtures thereof. Preferably, sodium bicarbonate is used in the invention.
The amount of acidic agent in the formulation of the invention is between 0,5 and 60% by weight, preferably between 1 and 50%, more preferably between 2 and 40% by weight in the total composition
In the formulation of e invention, the acidic agent is selected from the group comprising malic acid, fumaric acid, citric acid, adipic acid, acetic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, tartaric acid or mixtures thereof. Preferably, citric acid is used in the invention.
The amount of sweetener in the formulation of the invention is in the ratio of 0,01 to 30%, preferably 0,05 to 20%, more preferably 0,1 to 10% by weight of the total composition.
In the formulation of the invention, sweeteners comprise, but are not limited to, saccharin sodium, aspartame, sucralose, glucose, lactose, fructose and other sugars, or taumatin, mogroside, inulin, mannitol, sorbitol, xylitol, erythritol and other sugar alcohols or mixtures thereof. Preferably, sucralose is used in the invention.
The amount of the aroma in the formulation of the invention is in the ratio of 0,01 to 30%, preferably 0,05 to 20%, more preferably 0,1 to 10% by weight of the total composition.
The aromatic agents of the invention comprise, but are not limited to, fruit flavors such as orange, banana, strawberry, cherry, bird cherry, lemon, and other flavors
such as cardamom, anise, peppermint, menthol, vanillin and ethyl vanillin, and mixtures thereof.
In the formulation of the invention, disintegrant is selected from alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulfate, sodium carboxymethyl cellulose, croscarmellose sodium, crospovidone, carboxymethyl cellulose calcium, doucat sodium, guar gum, low substitute hydroxypropyl cellulose, polyacrylene potassium, poloxamer, povidone, sodium alginate, sodium glycine carbonate, sodium lauryl sulfate or mixtures thereof. Preferably, crospovidone is used in the invention.
Surprisingly, according to this embodiment of the present invention, the use of crospovidone as a disintegrant in the ratio of 0,1% to 15%, preferably 1% to 8%, more preferably 2% to 4% by weight in the total composition allowed for a formulation with the desired water solubility time and improved patient compliance.
Surprisingly, according to this embodiment of the present invention, the ratio of the total active ingredient to the disintegrant in the range of 0,1 - 50, preferably 0,125 - 40, more preferably 0,125 - 30, more preferably 0,5 - 30, more preferably 1 - 20 and most preferably 2,5 - 10 by weight in the formulation allowed for an effervescent tablet formulation of dapagliflozin and metformin with very good dissolution and solubility ratio, thereby high bioavailability, forming a neutral and clear solution that doesn’t leave any residues or precipitates after dissolution.
Surprisingly, according to this embodiment of the present invention, the ratio of the active ingredient dapagliflozin with low solubility to the disintegrant in the range of 0,001 - 5, preferably 0,00125 - 1 , more preferably 0,01 - 0,5, more preferably 0,0125 - 0,1 by weight in the formulation allowed for an effervescent tablet formulation of dapagliflozin and metformin with very good dissolution and solubility ratio, thereby high bioavailability, forming a neutral and clear solution that doesn’t leave any residues or precipitates after dissolution.
Polyethylene glycol (PEG) is a water-soluble lubricant and is stable. Polyethylene glycol also does not cause over-mixing problems and is not hygroscopic. Since it is
not hygroscopic, it does not harm the manufacture apparatus. Furthermore, polyethylene glycol can perform more than one function in the formulation of the present invention. For example, it can function both as a lubricant and as a stabilizer. This helps the formulation to remain stable throughout its shelf life. Preferably, PEG 6000 is used in the invention.
According to this embodiment of the present invention, the amount of lubricant is 0,1 to 30%, preferably 0,5 to 15%, more preferably 1 to 5% by weight in the total composition.
Another embodiment of the present invention is a method for the preparation of effervescent tablet formulation, comprising the following steps; a. Granulating, drying and sieving dapagliflozin, metformin and mannitol using alcohol b. Mixing the granules with sodium bicarbonate, citric acid, sucralose, aroma and crospovidone to obtain homogeneity c. Adding PEG 6000 and mixing further for a short period of time to obtain a homogeneous mixture. d. Finalising the mixture and pressing into the tablets under low humidity conditions adimlarini igermektedir.
The present invention is described in more detail by the following examples. The example is not to limit the scope of the invention, but should be considered in the light of the details described above.
Example 1 :
The above-mentioned pharmaceutical formulation is prepared as follows:
Granulating, drying and sieving dapagliflozin, metformin and mannitol using alcohol. Mixing this granule with sodium bicarbonate, citric acid, sucralose, aroma and crospovidone to obtain homogeneity. Adding polyethylene glycol (PEG 6000) and mixing further for a short period of time to obtain a homogeneous mixture. Obtaining the final mixture and pressing into the tablets under low humidity conditions Pressing to form 4-5 g tablet. Example 2:
The above-mentioned pharmaceutical formulation is prepared as follows:
Granulating, drying and sieving dapagliflozin, metformin and mannitol using alcohol. Mixing this granule with sodium bicarbonate, citric acid, sucralose, aroma and crospovidone to obtain homogeneity. Adding polyethylene glycol (PEG 6000) and mixing further for a short period of time to obtain a homogeneous mixture. Obtaining
the final mixture and pressing into the tablets under low humidity conditions Pressing to form 4-5 g tablet.
Example 3:
The above-mentioned pharmaceutical formulation is prepared as follows:
Granulating, drying and sieving dapagliflozin, metformin and mannitol using alcohol. Mixing this granule with sodium bicarbonate, citric acid, sucralose, aroma and crospovidone to obtain homogeneity. Adding polyethylene glycol (PEG 6000) and mixing further for a short period of time to obtain a homogeneous mixture. Obtaining the final mixture and pressing into the tablets under low humidity conditions pressing to form 4-5 g tablet.
Suprisingly, this invention provides an effervescent tablet formulation of dapagliflozin and metformin that is stable and has very good dissolution and solubility ratio, thereby high bioavailability, that does not stick to the manufacture apparatus during production, creates a stable, neutral and clear solution against moisture, does not leave any residues or precipitates after dissolution and provides a delicious taste, does not leave an unpleasant and bitter taste.
Claims
1. An effervescent tablet formulation, comprising a combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
2. The effervescent tablet composition according to Claim 1 , wherein the composition comprises dapagliflozin or a pharmaceutically acceptable salt thereof in the ratio of 0,001 to 5%, preferably 0,01 to 1%, and more preferably 0,05 to 0,2% by weight of the total formulation and metformin or a pharmaceutically acceptable salt thereof being present in the ratio of 1 to 50%, preferably 5 to 30%, and more preferably 10 to 20% by weight of the total formulation.
3. The effervescent tablet composition according to Claim 1 or 2, wherein more than one pharmaceutically acceptable excipients are selected from the group consisting of fillers, alkali agents, acidic agents, sweeteners, aromatic agents, disintegrants, lubricants, or mixtures thereof.
4. The effervescent tablet composition according to Claim 3, wherein the amount of the disintegrant is present in the ratio of 0,1% to 15%, preferably 1% to 8%, more preferably 2% to 4% by weight in the total composition.
5. The effervescent tablet composition according to Claim 3, wherein the ratio of the total active ingredient to the disintegrant is in the range of 0,1 - 50, preferably 0,125 - 40, more preferably 0,125 - 30 by weight.
6. The effervescent tablet composition according to Claim 4 or 5, wherein the disintegrant is selected from alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulfate, sodium carboxymethyl cellulose, croscarmellose sodium, crospovidone, carboxymethyl cellulose calcium, doucat sodium, guar gum, low substitute hydroxypropyl cellulose, polyacrylene potassium, poloxamer, povidone, sodium alginate, sodium glycine carbonate, sodium lauryl sulfate or mixtures thereof, which is preferably crospovidone.
7. The effervescent tablet composition according to Claim 3, wherein the amount of the filler is present in the ratio of 1% to 80%, preferably 3% to 70% and more preferably 5% to 60% by weight in the total composition.
8. The effervescent tablet composition according to Claim 3, wherein the ratio of the total active ingredient to the filler is in the ratio of 0,01 to 30, preferably 0,015 to 20, more preferably 0,05 to 10.
9. The effervescent tablet composition according to Claim 7 and 8, wherein the filler is selected from sugars, mannitol, sorbitol, sucrose, inorganic salts, calcium salts, polysaccharides, dextrose, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixtures, xylitol, trehalose or mixtures thereof, which is preferably mannitol.
10. The effervescent tablet composition according to Claim 3, wherein the alkali agent is present in the range of 0,5 to 60%, preferably 1 to 50%, more preferably 2 to 40% by weight in the total composition.
11. The effervescent tablet composition according to Claim 10, wherein the alkali agent is selected from sodium bicarbonate, sodium glycine carbonate, ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, trolamine or mixtures thereof, which is preferably sodium bicarbonate.
12. The effervescent tablet composition according to Claim 3, wherein the acidic agent is present between 0,5 and 60% by weight, preferably between 1 and 50%, more preferably between 2 and 40% by weight in the total composition.
13. The effervescent tablet composition according to Claim 12, wherein, the acidic agent is selected from the group comprising malic acid, fumaric acid, citric acid, adipic acid, acetic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, tartaric acid or mixtures thereof, which is preferably citric acid.
14. The effervescent tablet composition according to Claim 3, wherein the lubricant is present in the range of 0,1 to 30%, preferably 0,5 to 15%, more preferably 1 to 5% by weight in the total composition.
15. The effervescent tablet composition according to Claim 14, wherein the lubricant is polyethylene glycol.
16. The effervescent tablet composition according to the preceding claims, wherein the composition comprising the following; a. 0,001 to 5% by weight of dapagliflozin or a pharmaceutically acceptable salt thereof
b. 1 - 50% by weight of metformin or a pharmaceutically acceptable salt thereof c. 1 - 80% by weight of mannitol d. 0,5 - 60% by weight of sodium bicarbonate e. 0,5 - 60% by weight of citric acid f. 0,01 - 30% by weight of sucralose g. 0,01 - 30% by weight of aroma h. 0,1 - 15% by weight of crospovidone i. 0,1 - 30% by weight of polyethylene glycol
17. The effervescent composition according to the preceding claims, wherein the composition comprising the following production method; a. Granulating, drying and sieving dapagliflozin, metformin and mannitol using alcohol. b. Mixing the granules with sodium bicarbonate, citric acid, sucralose, aroma and crospovidone to obtain homogeneity. c. Adding polyethylene glycol and mixing further for a short period of time to obtain a homogeneous mixture. d. Finalising the mixture and pressing into the tablets under low humidity conditions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20866500.0A EP4031122A4 (en) | 2019-09-16 | 2020-08-05 | Effervescent tablet formulations comprising dapagliflozin and metformin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2019/14043A TR201914043A1 (en) | 2019-09-16 | 2019-09-16 | EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN |
| TR2019/14043 | 2019-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021054912A1 true WO2021054912A1 (en) | 2021-03-25 |
Family
ID=74883168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2020/050687 WO2021054912A1 (en) | 2019-09-16 | 2020-08-05 | Effervescent tablet formulations comprising dapagliflozin and metformin |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4031122A4 (en) |
| TR (1) | TR201914043A1 (en) |
| WO (1) | WO2021054912A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022225489A1 (en) * | 2021-04-21 | 2022-10-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038979A1 (en) * | 2005-09-22 | 2007-04-12 | Swissco Development Ag | Effervescent metformin composition and tablets and granules made therefrom |
| WO2013115743A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Effervescent tablet formulations comprising the combination of voglibose and metformin |
| US20150238421A1 (en) | 2009-11-13 | 2015-08-27 | Astrazeneca Ab | Bilayer Tablet Formulations |
| WO2017098481A1 (en) * | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
| WO2018185669A1 (en) | 2017-04-07 | 2018-10-11 | Zenvision Pharma Llp | Effervescent compositions comprising saxagliptin or salt thereof |
-
2019
- 2019-09-16 TR TR2019/14043A patent/TR201914043A1/en unknown
-
2020
- 2020-08-05 WO PCT/TR2020/050687 patent/WO2021054912A1/en unknown
- 2020-08-05 EP EP20866500.0A patent/EP4031122A4/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038979A1 (en) * | 2005-09-22 | 2007-04-12 | Swissco Development Ag | Effervescent metformin composition and tablets and granules made therefrom |
| US20150238421A1 (en) | 2009-11-13 | 2015-08-27 | Astrazeneca Ab | Bilayer Tablet Formulations |
| WO2013115743A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Effervescent tablet formulations comprising the combination of voglibose and metformin |
| WO2017098481A1 (en) * | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
| WO2018185669A1 (en) | 2017-04-07 | 2018-10-11 | Zenvision Pharma Llp | Effervescent compositions comprising saxagliptin or salt thereof |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP4031122A4 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022225489A1 (en) * | 2021-04-21 | 2022-10-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4031122A4 (en) | 2023-08-30 |
| TR201914043A1 (en) | 2021-04-21 |
| EP4031122A1 (en) | 2022-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200938210A (en) | Pharmaceutical compositions | |
| US20130274342A1 (en) | Compositions and methods for treating cough | |
| EP2661252A1 (en) | Water soluble dosage forms | |
| EP2563340A2 (en) | Water soluble pharmaceutical composition | |
| EP2848242A1 (en) | Orally disintegrating formulations of Linagliptin | |
| WO2021054912A1 (en) | Effervescent tablet formulations comprising dapagliflozin and metformin | |
| US20110257159A1 (en) | Orally disintegrating tablet formulations of mirtazapine and process for preparing the same | |
| JP4814636B2 (en) | Biguanide drugs for internal use | |
| US10016359B2 (en) | Solid forms containing meloxicam with improved buccal taste and process for their preparation | |
| WO2018185669A1 (en) | Effervescent compositions comprising saxagliptin or salt thereof | |
| KR101046789B1 (en) | Amlodipine quick disintegrating tablet with improved stability and preparation method thereof | |
| EP2248516A1 (en) | Orally disintegrating compositions of emoxypine | |
| WO2004089343A1 (en) | Water soluble tablets | |
| CN104434860A (en) | Ambroxol hydrochloride osmotic pump type pharmaceutical composition prepared by inclusion process | |
| DK3174521T3 (en) | PEDIATRIC CHEESE TABLE CONTAINING ANTIVIRAL AGENT AND METHOD OF PRODUCING THEREOF | |
| JP2010053048A (en) | Irbesartan-containing pharmaceutical composition having mitigated bitter taste | |
| WO2024023786A1 (en) | Orally disintegrating palatable formulations of drotaverine and method of preparation thereof | |
| CN103282038A (en) | Phosphomycin pharmaceutical composition | |
| US9849147B2 (en) | Pharmaceutical composition containing phosphate binding polymer | |
| GB2619970A (en) | An orodispersible pharmaceutical composition of baclofen and its process of preparation | |
| JP2022135317A (en) | Linagliptin preparation | |
| WO2021194446A1 (en) | A sachet formulation comprising metformin and dapagliflozin | |
| EP1608341A1 (en) | Water-soluble tablets of metformin | |
| JP2022170891A (en) | Oral solid preparation | |
| WO2022106923A1 (en) | Orodispersible powder composition comprising an antihistamine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20866500 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020866500 Country of ref document: EP Effective date: 20220419 |